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Abstract
Background—Hypoplastic left heart syndrome (HLHS) has been associated with germline 
mutations in 12 candidate genes and a recurrent somatic mutation in HAND1 gene. Using targeted 
and whole exome sequencing (WES) of heart tissue samples from HLHS patients, we sought to 
estimate the prevalence of somatic and germline mutations associated with HLHS.
Methods—We performed Sanger sequencing of the HAND1 gene on 14 ventricular (9 LV and 5 
RV) samples obtained from HLHS patients, and WES of 4 LV, 2 aortic and 4 matched PBMC 
samples, analyzing for sequence discrepancy. We also screened for mutations in the 12 candidate 
genes implicated in HLHS.
Results—We found no somatic mutations in our HLHS cohort. However, we detected a novel 
germline frameshift/stop-gain mutation in NOTCH1 in a HLHS patient with a family history of 
both HLHS and hypoplastic right heart syndrome (HRHS).
Conclusion—Our study, involving one of the first familial cases of single ventricle defects 
linked to a specific mutation, strengthens the association of NOTCH1 mutations with HLHS, and 
suggests that the two morphologically distinct single ventricle conditions, HLHS and HRHS, may 
share a common molecular and cellular etiology. Finally, somatic mutations in the LV are an 
unlikely contributor to HLHS.
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Introduction
Hypoplastic left heart syndrome (HLHS) affects 1 of every 4,344 newborns and is one of the 
most devastating forms of congenital heart disease (CHD) [1]. In HLHS, the left ventricle 
(LV) is severely underdeveloped, forming a vestigial chamber. HLHS is uniformly fatal 
without multi-stage palliative surgeries or cardiac transplantation [2,3].
The precise pathogenesis of HLHS is unknown, but evidence supports a genetic etiology [4–
6]. HLHS is highly heritable, with a 500-fold increased incidence among siblings and a 
1000-fold increase if a parent has any form of CHD [6]. Moreover, human genetic studies 
demonstrate a linkage to chromosome 2p15 [7], and a large scale sequencing study recently 
implicated the role of de novo mutations in HLHS, although it did not establish a definitive 
causality [5]. In addition, mutations in several genes are associated with HLHS, including 
FOXC2[8], FOXL1[8], GJA1[9], HAND1[10], IRX4[11], MYH6[12], NKX2.5[13], 
NOTCH1[14, 15] and TBX5[16].
Somatic mutations are implicated in atrial fibrillation and in various CHD, including HLHS. 
Reamon-Buettner and colleagues demonstrated a somatic mutation in the HAND1 gene, 
confined to the hypoplastic left ventricle, but absent from adjacent tissue and peripheral 
blood, in HLHS patients [17]. They found 24 of 31 ventricular samples had a recurrent 
frameshift mutation (A126fs) in the basic helix- loop-helix (bHLH) DNA binding domain of 
HAND1. Evidence refuting this finding was recently reported [18–20], but this study 
analyzed only the right ventricle, which is not the primary chamber affected in HLHS, 
leaving open the crucial possibility that a somatic mutation restricted to the developing left 
ventricle resulted in HLHS. Lastly, no study has looked for somatic mutations in HLHS 
beyond the HAND1 gene.
Recently, germline mutations in NOTCH1 and several other genes have been implicated in 
HLHS. Garg and colleagues found that frameshift and nonsense mutations in NOTCH1 are 
strongly associated with a spectrum of developmental aortic valve anomalies, providing the 
first human genetic evidence that NOTCH1 mutations cause CHD [14]. Interestingly, some 
patients with NOTCH1 mutations had other CHDs, including one HLHS case. Subsequently, 
2 HLHS patients were found to carry de novo mutations in NOTCH1[15], and another was 
found to be compound heterozygous for novel missense NOTCH1 variants [21]. Finally, in a 
study of 428 CHD proband, gross NOTCH1 mutations (splicing mutations, truncations and 
whole gene deletion) were found in 7% of familial L-CHD and 1% of sporadic L-CHD [22]. 
Interestingly, only 2 of 63 families with NOTCH1 mutation had a child with HLHS, 
suggesting NOTCH1 mutations causing HLHS may be rare.
We sought to test the hypothesis that mutations, and possibly somatic mutations in the 
developing LV, may contribute to HLHS pathogenesis. To identify mutations, we performed 
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both targeted and whole exome sequencing (WES) of DNA isolated from LV tissue, the 
corresponding aortic outflow tract (OFT), and the peripheral blood mononuclear cells 
(PBMCs) obtained from HLHS patients.
Methods
Source of the tissue samples and blood and DNA isolation
We acquired tissue from 14 HLHS patients, including 9 left ventricle, 5 right ventricle, 4 
corresponding PBMC and 2 corresponding outflow tract samples (Table 1). Specimens were 
obtained from Vanderbilt Pediatric CHD Biorepository. The study was approved by 
Vanderbilt Institutional Review Board, and written informed consent was obtained from all 
heart tissue and blood sample donors. Blood samples were collected in BD Vacutainer® 
EDTA tubes (Becton, Dickinson and Company, NJ) prior to heart transplantation. Heart 
tissues were collected immediately after explant and were flash frozen in liquid nitrogen. 
Blood and tissues were stored in −80°C till used for DNA extraction. Patients had a 
confirmed diagnosis of HLHS at the time of tissue sample collection. DNA was extracted 
from these specimens using Qiagen DNeasy Blood & Tissue Kit Kit (Qiagen, Cat No. 
69504) according to Manufacturer’s instructions.
Sequencing of HAND1
We amplified the HAND1 gene from 14 ventricular DNA samples by Polymerase Chain 
reaction (PCR) using AmpliTaq Gold® 360 Master Mix (ThermoFisher Scientific). We 
designed 5 primer sets covering 1996 bps including the 3 exons as well as flanking intronic 
regions (Supplement 1). We performed bidirectional Sanger sequencing utilizing BigDye 
Terminator chemistry sequencing kit and Applied Biosystems DNA Analyzer.
Whole exome sequencing comparison of PBMC and LV tissue samples for somatic 
mutation analysis
We completed WES on 10 samples including 4 ventricular samples, 2 outflow tract samples 
and 4 PBMCs (Table 1). The WES was performed at the Vanderbilt Advanced Genomics 
Core Facility using Illumina HiSeq 2500 with 100× coverage. Data were processed through 
Illumina’s CASAVA v1.8.2 pipeline. We conducted thorough quality control based on the 
multi-stage quality control protocol developed at Vanderbilt [23, 24]. No sequencing quality 
concerns were observed. Alignments were performed using BWA[25] against human 
genome reference UCSC HG19. We marked duplicates using Picard[26], then performed 
local realignment and recalibration using the Genome Analysis Toolkit (GATK)[27]. 
Somatic mutations were inferred using GATK’s analysis pipeline. The results were further 
filtered based on GATK’s best practice. Annotations of SNV were performed using 
ANNOVAR[28].
Confirmatory Sanger sequencing of whole exome sequencing variants
We identified 271 sequence variations between blood and left ventricle (Figure 2). These 
variants were further filtered, and 71 instances of discrepancy with a read depth > 4,0 were 
identified. This low-stringent cutoff was meant to increase the sensitivity of detecting a 
somatic mutation in our sample, at the cost of lowering specificity[29]. Further filtering 
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using a MAF<1% left only 24 instances of sequence discrepancy in 14 genes: BRD4, 
DMRTB1, FLJ44313, GLTSCR1, GPR153, HNRNPCL1, IQSEC2, MMP17, OGFRL1, 
POTED, RERE, RP1L1, SAMD1 and SETD8. We performed confirmatory Sanger 
sequencing of these 24 variants. In addition, we performed Sanger sequencing on 40 other 
variants in 12 additional genes based on loose biological plausibility: C16orf71, CES1, 
COL4A4, EP400, EVX2, IFNA1, MADCAM1, MUC4, NOTCH2, PIEZO1, ZNF676 and 
ZNF845. In total, these 64 variants were located in 26 genes, and covered by 26 primer sets 
(Data Supplemental 1).
Mutation screening of whole exome sequencing data
In total, WES identified 36,426 single nucleotide variants (SNV) in the 10 tissue samples 
from 4 patients (Figure 3; Table 2). We first focused our analysis on 20 genes previously 
implicated in HLHS or ventricular development (BMP2, FOXC2, FOXL1, GJA1, HAND1, 
HEY1, HEY2, HUWE1, IRX4, JAG1, MED20, MLL2, MYH6, NKX2-5, NOTCH1, 
NOTCH2, PTCH1, TBX2, TBX5 and USP44)[8–14, 16, 30, 31]. After comparing our 
sequencing results to the reference sequence UCSC hg19 [32], we found 8 SNVs which led 
to nonsynonymous codon changes (Figure 3A). Only 1, c.C4662A substitution in NOTCH1, 
had MAF<1%. Sanger sequencing was performed to confirm this mutation (Figure 3B).
Results
HAND1 frameshift (A126fs) mutation, previously reported to be commonly associated with 
HLHS, is not present in HLHS ventricular samples
We sought to test whether mutations in HAND1 are present in left ventricular tissues of 
HLHS patients, as previously reported (17). We used DNA isolated from fresh frozen 
ventricle samples from 14 HLHS patients (9 LV and 5 RV samples) as described above 
(Figure 1A (Table 1)). HAND1 is a 3.3kb gene consisting of 2 exons (Figure 1B). First, we 
sequenced a 533-basepair (bp) region of exon 2 containing the previously reported frame 
shift (A126fs) mutation. The A126fs mutation was absent in the 14 HLHS ventricular 
samples (Figure 1C). To rule out possible mutations elsewhere in HAND1, we sequenced a 
1996-bp region consisting of all exons (1 and 2), the flanking introns, and a portion of the 
intergenic regions from all 14 HLHS patients’ ventricles, and found no sequence variant in 
HAND1. Finally, WES analysis of LV tissue from 4 of the HLHS patients did not identify a 
HAND1 mutation (Figure 1D).
Whole exome sequencing of left ventricular tissue and peripheral blood failed to 
demonstrate somatic mutation in HLHS
We also investigated the contribution of somatic mutations to HLHS beyond HAND1 at the 
exome wide level. We performed WES of 4 LV samples, 4 corresponding PBMC samples 
and 2 corresponding outflow tract (OFT) samples (Figure 2; Table 1). We then compared the 
sequences from each patient’s LV and OFT samples with the same patient’s PBMC samples. 
The initial analysis identified 271 single nucleotide variations (SNVs) of potential 
discrepancies between PBMCs and LV/OFT tissues; however, each variant was in an area of 
low sequence coverage, suggesting these may be sequencing artifacts. Indeed, only 71 of 
271 potential discrepant variants met the relatively low stringent filtering criterion of a read 
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depth >4,0 for increased sensitivity (recent studies use read depth >20 for somatic mutation 
calls [33]). As discussed above, we did not identify a somatic mutation in HAND1. Of the 
71 variants, 47 found in LV/OFT tissues but not in PBMCs corresponded to known SNVs 
with a minor allele frequency (MAF) of >1%; therefore, we attributed these to erroneous 
variant calls in PBMC samples. Finally, we focused on the remaining 24 candidates that had 
a MAF <1%. To validate the initial WES results, we performed Sanger sequencing of 24 
putative discrepant variants in 14 genes: BRD4, DMRTB1, FLJ44313, GLTSCR1, GPR153, 
HNRNPCL1, IQSEC2, MMP17, OGFRL1, POTED, RERE, RP1L1, SAMD1 and SETD8 
(Supplementary Data 1). We also performed Sanger sequencing on 40 additional potential 
discrepant variants in 12 genes based on novelty and predicted pathogenicity, and biological 
plausibility even though they did not meet the above, low-stringent filtering criteria: 
C16orf71, CES1, COL4A4, EP400, EVX2, IFNA1, MADCAM1, MUC4, NOTCH2, 
PIEZO1, ZNF676 and ZNF845. In summary, our Sanger sequencing of the 64 potential 
discrepant variants in 26 genes showed 100% match between blood and ventricular tissue, 
confirming our suspicion that the initial discrepancies were due to erroneous variant calls at 
low read depths. We detected no somatic mutations in the HLHS cases examined.
Mutation Screening of HLHS samples identified a novel NOTCH1 truncation
From the WES of tissue sample of 4 HLHS patients, we identified total of 36,426 SNV calls, 
which are under ongoing further investigation. Of these, we focused on 20 genes previously 
implicated in HLHS or ventricular development (8–14, 16, 28, 29): BMP2, FOXC2, FOXL1, 
GJA1, HAND1, HEY1, HEY2, HUWE1, IRX4, JAG1, MED20, MLL2, MYH6, NKX2-5, 
NOTCH1, NOTCH2, PTCH1, TBX2, TBX5 and USP44, and found 41 potential single 
nucleotide variants of which 8 were nonsynonymous changes (Figure 3A; Table 2). Of these, 
only 1 had a minor allele frequency (MAF) <1%. This variant, found in Patient 111 (Table 
1), is a novel C to A substitution at position c.4662 (c.C4662A) of NOTCH1 gene, which 
produces a premature stop codon replacing cysteine-1554 (p.C1554stop) in a Lin/NOTCH 
repeat (LNR) region of the extracellular domain (Figure 3C). Bidirectional sequencing 
confirmed that Patient 111 was heterozygous for this novel mutation, which appeared to be 
germline-derived based on sequencing of the patient’s LV, OFT, PBMCs and his parent’s 
DNA isolated from PBMCs (Figure 3B). We identified the same heterozygous mutation in 
the patient’s father, though he is not affected by CHD. Interestingly, the patient’s deceased 
paternal aunt was known to have a hypoplastic right ventricle; however, we did not have 
access to her tissue (Table 1).
Discussion
Increasing evidence supports a strong genetic component to HLHS pathogenesis, but despite 
extensive sequencing, the etiology remains unknown. Somatic mutations are implicated in 
atrial fibrillation and a variety of CHD [34, 35]; however, these results have not been 
reproducible. According to Reamon-Buettner et al, a recurrent somatic mutation in the 
HAND1 gene was found in the majority (24 of 31) of the HLHS LV samples they studied 
[17]. Although this finding was refuted by Esposito et al [18], the latter study only examined 
right ventricle tissues, leaving open the crucial possibility of a somatic mutation within the 
developing left ventricle. Here, in examination of 14 HLHS ventricular samples, we found 
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no evidence of somatic nor germline mutation in HAND1. We note that, in the study by 
Reamon-Buettner and colleagues, DNA was obtained from ventricles fixed in formalin 
whereas our DNA samples were prepared from flash frozen tissue freshly obtained at the 
time of cardiac surgery[17, 34]. Since formalin fixation is known to cross link cytosine 
nucleotides, typically resulting in C to T (G to A) transitions [36], and fresh frozen tissue 
sequencing results are often contradictory [37, 38], we speculate that the earlier findings 
represent sequencing artifact due to formalin fixation of tissue samples. Our finding raises 
caution over claims of mutations based on sequencing from formalin fixed tissue samples. 
To our knowledge, this study is the first attempt to look for potential somatic mutations in 
hypoplastic LV tissues beyond HAND1. Our whole exome wide search for a somatic 
mutation in matched LV tissue samples from 4 HLHS patients failed to identify a somatic 
mutation. Given our small sample size, this study does not rule out a potential role of 
somatic mutations in pathogenesis of HLHS, but it suggests that recurrent mutations in 
HAND1 are not frequently involved in HLHS.
In one of he 14 HLHS patients, WES identified a novel, germline, nonsense mutation 
(c.C4662A) in NOTCH1, which encodes a transmembrane receptor involved in cell fate 
decisions. The variant carrier (patient 111) was heterozygous for this mutation, which 
replaces a stop codon for cysteine-1554. Since the predicted mutant protein lacks the entire 
transmembrane and cytoplasmic domains (Figure 3), it is highly likely that the truncated 
Notch1 is nonfunctional or pathogenic. The index patient’s father, who does not have 
significant CHD, also carried this mutation in heterozygous state, indicating variable 
penetrance. While most previously reported HLHS cases are not associated with a NOTCH1 
mutation [22], our study strengthens the growing association of NOTCH1 mutations and 
HLHS [14, 22, 30, 31].
Interestingly the patient’s paternal aunt (now deceased) was diagnosed with hypoplastic 
right heart syndrome (HRHS), and had undergone palliative surgery as an infant. To our 
knowledge, this is the first report of a NOTCH1 mutation associated with familial cases of a 
single ventricle defect, a spectrum of severe congenital heart defects including HLHS and 
HRHS, which are characterized by only one adequate-sized functional ventricle. A key 
unanswered question in HLHS pathophysiology is whether underdeveloped LV is a primary 
defect in LV morphogenesis or secondary to OFT abnormalities such as obstruction. 
Growing association of NOTCH1 mutations with both OFT abnormalities and HLHS 
suggests a common pathogenesis, with modifier genes playing an important role. Our 
finding that a common NOTCH1 mutation may be associated with both HLHS and HRHS 
lend support to the notion that, in some cases, defective OFT morphogenesis, rather than 
defective ventricular morphogenesis, may be primarily responsible for single ventricle 
defects. Future studies may provide insight by measuring expression of NOTCH1 and its 
downstream molecules at different regions within the heart, including the left ventricle, right 
ventricle and outflow tract.
HLHS was universally fatal until multi-staged palliative surgery began to prolong survival 
within the past two decades, though morbidity and mortality remain high. In recent years, 
two experimental approaches have been developed to treat HLHS. The first, fetal aortic 
valvuloplasty, was developed with the hope that alleviating outflow tract obstruction during 
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fetal development will improve outcome[39]. However, significant portion of patients fail to 
respond to this very high-risk procedure, and current guidelines that rely only on fetal 
echocardiographic features are ineffective in predicting therapeutic response[40]. An 
alternative approach, based on the premise that intrinsic deficit in cardiomyocyte 
proliferation is responsible for HLHS, involves transfer of cardiac progenitor cells to 
hypoplastic heart [41,42]. Further investigation into genetic causes of HLHS, including the 
role of critical modifier genes, as well as the induced pluripotent stem cell-based models of 
HLHS [21], are needed to differentiate potential myocyte intrinsic and extrinsic etiology. In 
summary, a better understanding of HLHS pathophysiology at the genetic and cell biological 
levels will herald a genome-informed individualized treatment plan for HLHS.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. No mutation was found in HAND1 in left ventricle of HLHS patients
(A) Using the Vanderbilt Congenital Heart Disease Tissue Bank, we isolated fresh frozen 
left ventricular (LV) and right ventricular (RV) tissue from 14 HLHS patients. (B) We 
amplified and sequenced a 1996 bp segment including HAND1’s entire coding region and a 
majority of the noncoding region. This included the Exon 1, which encodes the bHLH 
domain, previously reported to be the site of a recurrent somatic mutation (A126fs) in 24 of 
31 HLHS LVs examined (17). (C) Shown are sequences corresponding to A126 in 9 HLHS 
LV and 5 HLHS RV samples. There were no mutations detected in this region or elsewhere 
in the HAND1 coding region.
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Figure 2. Exome wide search for somatic mutation in four HLHS patients
Right, Schema for validation of putative somatic mutations identified by WES. We 
examined 10 tissue samples including 4 patients’ LVs and PBMCs, and additional outflow 
tract (OFT) tissue in 2 of those patients. WES at the 100× coverage identified 271 sequence 
discrepancies between LV or OFT and the corresponding PBMCs. All were in areas of low 
sequence coverage. 71 discrepant sequences had a read depth > 4,0. Of these, only 24 had 
MAF <1%. Sanger sequencing of these 24 samples failed to confirm a somatic mutation. We 
also conducted Sanger sequencing on 40 additional discrepant variants based on biological 
plausibility (see text), and found no somatic mutation. Left, breakdown of WES results by 
patients.
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Figure 3. Search for mutations in genes previously implicated in HLHS reveals a novel 
truncation mutation in NOTCH1
(A) In WES of 10 samples of HLHS patients’ left ventricular tissue, outflow tract, and 
blood, we focused on 20 genes previously associated with to HLHS or ventricular 
development. We detected total of 41 SNVs (Table 2). Of these, 10 were nonsynonymous 
changes, and only 1 had a MAF <1%. This mutation was a premature stop codon in the 
NOTCH1 gene. (B) Sanger sequencing of patient 111’s PBMC confirmed the mutation, a 
heterozygous A to C transversion, creating a stop codon at C1554. (C) The predicted mutant 
Notch1 protein was truncated at the Lin/NOTCH repeat (LNR) region of the extracellular 
domain, hence lacking the transmembrane (TM) and intracellular signaling domains. Also 
shown are RBP J-associated molecule (RAM) domain, ankyrin (ANK) domain and PEST 
domain.
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